Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To improve myasthenia gravis (MG) autoantibody testing.
Methods MG serologic tests with confirmatory or refuting clinical–electrodiagnostic (EDX) testing and cancer evaluations were reviewed over 4 years (2012–2015). All patients had acetylcholine receptor–binding (AChR-Bi), modulating (AChR-Mo), and striational (STR) autoantibody testing, and negatives reflexed to muscle-specific kinase (MuSK). Thymoma and cancer occurrences were correlated with STR and reflexed glutamic acid decarboxylase 65 (GAD65), ganglionic acetylcholine receptor (α3), collapsin response mediating protein-5, and voltage-gated potassium channel complex autoantibodies.
Results Of 433 samples tested, 133 (31%) met clinical–EDX criteria for MG. Best sensitivity (90%) occurred at AChR-Bi >0.02 nmol/L, leaving 14 negative (6 ocular MG, 7 generalized MG, 1 MuSK MG) with specificity 90% (31 false-positives). Using AChR-Mo antibodies (>20% loss), specificity was better (92%, 24 false-positives), but sensitivity dropped (85%). Specificity improved (95%) by testing AChR-Mo when AChR-Bi are positive, resulting in 45% reduction of false-positives (31–17), maintaining AChR-Bi 90% sensitivity. Cutoff values recommended by area under the curve analysis did not outperform this approach. AChR-Bi and AChR-Mo values were significantly higher in true-positives. CT evaluations in 121 MG samples revealed 16 thymomas. Historical or subsequent cancers occurred in 22. STR and reflexed autoantibodies were not more common in MG with thymoma or other cancers. Full-body CT (n = 34) was performed in those with STR and reflex autoantibody positivity, but without additional cancers found.
Conclusion Accuracy of MG serologic testing is improved by reflexing AChR-Bi–positive cases to AChR-Mo. STR and other reflexed cancer evaluation autoantibodies did not provide value beyond standard CT chest imaging at the time of MG diagnosis. Diagnostic certainty is informed by AChR-Bi and AChR-Mo with higher values increasing specificity.
Glossary
- α3=
- ganglionic acetylcholine receptor;
- AChR=
- acetylcholine receptor;
- AChR-Bi=
- acetylcholine receptor binding;
- AChR-Mo=
- acetylcholine receptor modulating;
- AUC=
- area under the curve;
- CI=
- confidence interval;
- CRMP5=
- collapsin response mediator protein-5;
- EDX=
- electrodiagnostic;
- GAD65=
- glutamic acid decarboxylase-65;
- MCD=
- mean consecutive difference;
- MG=
- myasthenia gravis;
- MuSK=
- muscle-specific receptor tyrosine kinase;
- RNS=
- repetitive nerve stimulation;
- ROC=
- receiver operating characteristic;
- SFEMG=
- single-fiber EMG;
- STR=
- striational;
- VGKC=
- voltage-gated Kv1 potassium channel
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
↵* These authors contributed equally to this work.
- Received April 4, 2020.
- Accepted in final form July 22, 2020.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic PanelsShahar Shelly, John R. Mills, Divyanshu Dubey et al.Neurology, April 26, 2021 -
Articles
Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndromeVanda A. Lennon et al.Neurology, April 01, 1997 -
Editorial
Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia GravisAt the Junction Where It HappensRobert P. Lisak et al.Neurology, July 07, 2021 -
Article
High κ free light chain is a potential biomarker for double seronegative and ocular myasthenia gravisAdi Wilf-Yarkoni, Yifat Alkalay, Talma Brenner et al.Neurology: Neuroimmunology & Neuroinflammation, July 14, 2020